218 related articles for article (PubMed ID: 15978877)
1. Type 2 diabetes--therapy with dipeptidyl peptidase IV inhibitors.
Demuth HU; McIntosh CH; Pederson RA
Biochim Biophys Acta; 2005 Aug; 1751(1):33-44. PubMed ID: 15978877
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.
Lankas GR; Leiting B; Roy RS; Eiermann GJ; Beconi MG; Biftu T; Chan CC; Edmondson S; Feeney WP; He H; Ippolito DE; Kim D; Lyons KA; Ok HO; Patel RA; Petrov AN; Pryor KA; Qian X; Reigle L; Woods A; Wu JK; Zaller D; Zhang X; Zhu L; Weber AE; Thornberry NA
Diabetes; 2005 Oct; 54(10):2988-94. PubMed ID: 16186403
[TBL] [Abstract][Full Text] [Related]
3. 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity.
Yamazaki K; Yasuda N; Inoue T; Nagakura T; Kira K; Shinoda M; Saeki T; Tanaka I
J Pharmacol Exp Ther; 2006 Dec; 319(3):1253-7. PubMed ID: 16980568
[TBL] [Abstract][Full Text] [Related]
4. Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.
Green BD; Flatt PR; Bailey CJ
Diab Vasc Dis Res; 2006 Dec; 3(3):159-65. PubMed ID: 17160910
[TBL] [Abstract][Full Text] [Related]
5. Current advances and therapeutic potential of agents targeting dipeptidyl peptidases-IV, -II, 8/9 and fibroblast activation protein.
Chen SJ; Jiaang WT
Curr Top Med Chem; 2011; 11(12):1447-63. PubMed ID: 21510839
[TBL] [Abstract][Full Text] [Related]
6. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes.
Ahrén B; Schmitz O
Horm Metab Res; 2004; 36(11-12):867-76. PubMed ID: 15655721
[TBL] [Abstract][Full Text] [Related]
7. (2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
Tajima A; Yamamoto K; Kozakai A; Okumura-Kitajima L; Mita Y; Kitano K; Jingu S; Nakaike S
Eur J Pharmacol; 2011 Mar; 655(1-3):99-107. PubMed ID: 21262219
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological profile of ASP8497, a novel, selective, and competitive dipeptidyl peptidase-IV inhibitor, in vitro and in vivo.
Someya Y; Tahara A; Nakano R; Matsuyama-Yokono A; Nagase I; Fukunaga Y; Takasu T; Hayakawa M; Shibasaki M
Naunyn Schmiedebergs Arch Pharmacol; 2008 May; 377(3):209-17. PubMed ID: 18398600
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
Thornberry NA; Gallwitz B
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
[TBL] [Abstract][Full Text] [Related]
10. Role of dipeptidyl peptidase IV (DP IV)-like enzymes in T lymphocyte activation: investigations in DP IV/CD26-knockout mice.
Reinhold D; Goihl A; Wrenger S; Reinhold A; Kühlmann UC; Faust J; Neubert K; Thielitz A; Brocke S; Täger M; Ansorge S; Bank U
Clin Chem Lab Med; 2009; 47(3):268-74. PubMed ID: 19676138
[TBL] [Abstract][Full Text] [Related]
11. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
[TBL] [Abstract][Full Text] [Related]
12. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide.
Pederson RA; White HA; Schlenzig D; Pauly RP; McIntosh CH; Demuth HU
Diabetes; 1998 Aug; 47(8):1253-8. PubMed ID: 9703325
[TBL] [Abstract][Full Text] [Related]
13. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.
Kirby M; Yu DM; O'Connor S; Gorrell MD
Clin Sci (Lond); 2009 Sep; 118(1):31-41. PubMed ID: 19780719
[TBL] [Abstract][Full Text] [Related]
14. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats.
Pospisilik JA; Stafford SG; Demuth HU; Brownsey R; Parkhouse W; Finegood DT; McIntosh CH; Pederson RA
Diabetes; 2002 Apr; 51(4):943-50. PubMed ID: 11916911
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?
Deacon CF; Ahrén B; Holst JJ
Expert Opin Investig Drugs; 2004 Sep; 13(9):1091-102. PubMed ID: 15330741
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes.
Deacon CF; Holst JJ
Int J Biochem Cell Biol; 2006; 38(5-6):831-44. PubMed ID: 16242377
[TBL] [Abstract][Full Text] [Related]
17. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors.
Thomas L; Eckhardt M; Langkopf E; Tadayyon M; Himmelsbach F; Mark M
J Pharmacol Exp Ther; 2008 Apr; 325(1):175-82. PubMed ID: 18223196
[TBL] [Abstract][Full Text] [Related]
18. The therapeutic potential of inhibitors of dipeptidyl peptidase IV (DPP IV) and related proline-specific dipeptidyl aminopeptidases.
Augustyns K; Van der Veken P; Senten K; Haemers A
Curr Med Chem; 2005; 12(8):971-98. PubMed ID: 15853709
[TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus.
Holst JJ; Deacon CF
Curr Opin Pharmacol; 2004 Dec; 4(6):589-96. PubMed ID: 15525549
[TBL] [Abstract][Full Text] [Related]
20. Post-proline-cleaving peptidases having DP IV like enzyme activity. Post-proline peptidases.
Abbott CA; Yu D; McCaughan GW; Gorrell MD
Adv Exp Med Biol; 2000; 477():103-9. PubMed ID: 10849735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
